Présentation de l'entreprise
Castle Biosciences, Inc. operates as a specialized molecular diagnostics entity dedicated to delivering test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, atopic dermatitis, and uveal melanoma. The corporation functions within the broader Healthcare sector, specifically focusing on the Diagnostics & Research industry, which implies a reliance on advanced laboratory technologies and gene expression profiling to support clinical decision-making. The company currently commands a market capitalization of $748.93M and generates annual revenue of $344.23M while maintaining an employee base of 883 individuals. These financial figures indicate that Castle Biosciences occupies a mid-cap position in the diagnostic market, supported by a substantial cash reserve that provides significant operational runway relative to its current revenue scale.
Santé financière
The company reported revenue of $344.23M for the trailing twelve months, yet this figure contrasts sharply with a net income of -$24,158,000 and an EBITDA of -$2,039,000. The substantial gap between the positive revenue of $344.23M and the negative net income reveals a cost structure where operating expenses significantly outweigh gross profits, resulting in a profit margin of -7.0%. Despite the negative net income, the company generated positive free cash flow of $41.21M, which indicates strong financial flexibility and the ability to fund operations without relying on external financing. The gross margin stands at 79.4%, suggesting high value capture on product sales, whereas the operating margin of -4.4% and the negative EBITDA highlight ongoing structural costs before interest and taxes. On the balance sheet, the company holds $299.50M in cash against $37.02M in debt, creating a robust liquidity position. This disparity is further emphasized by a debt-to-equity ratio of 7.86, which, while appearing high, is offset by the massive cash hoard, suggesting a net conservative stance rather than a leveraged one. The current ratio of 5.26 demonstrates exceptional short-term liquidity, ensuring the firm can easily meet its obligations due within a year. Furthermore, the return on equity of -5.2% and return on assets of -2.6% reveal that management is currently generating negative returns on the capital employed, a common characteristic in high-growth diagnostic firms reinvesting heavily in research and development.
Évaluation de la valorisation
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is -46.33, implying that the market is pricing in future earnings recovery rather than current profitability. The price-to-book ratio of 1.59 indicates that the market values the company at a premium of 59% over its net asset book value, reflecting confidence in its intangible assets and future diagnostic pipeline. Additionally, the price-to-sales ratio of 2.18 and the EV/EBITDA of -238.57 suggest that traditional earnings-based valuation models are less applicable, and investors are relying on revenue multiples and asset backing instead. Regarding price levels, the stock trades between a 52-week low of $14.59 and a 52-week high of $44.28, with the current market price situated within this historical range. The beta of 1.19 signifies that the stock exhibits higher price volatility than the broader market, moving approximately 19% more aggressively in response to market-wide fluctuations.
Growth & Income
Revenue growth year-over-year stands at 0.8%, while earnings growth is N/A, indicating that the company is currently prioritizing market expansion over immediate profit scaling. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all earnings are theoretically available for reinvestment into growth initiatives such as new test development or market penetration. The absence of a dividend payout ratio confirms that Castle Biosciences retains earnings to fund its operational needs and strategic objectives rather than distributing cash to shareholders. Overall, the growth and income profile is defined by modest top-line expansion and a complete focus on capital retention to sustain long-term research and development efforts within the molecular diagnostics sector.